← back to search

Ran Hou

Hebei Medical University · CN
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Cancer-related molecular mechanisms research, Ferroptosis and cancer prognosis, Cancer Immunotherapy and Biomarkers, and Gastric Cancer Management and Outcomes.
h-index
4
citations
33
works
13
NIH funding
primary concept
email

Recent publications

Evaluation of the performance of screening tools for dysphagia in older adults: A diagnostic meta-analysis
Geriatric Nursing 2025cited by 4position: middledoi
The necroptosis-related lncRNA ENSG00000253385.1 promotes the progression of esophageal squamous cell carcinoma by targeting the miR-16-2-3p/VDAC1 axis
Scientific Reports 2025cited by 3position: middledoi
Effect of voice training intervention on swallowing function in patients with head and neck cancer undergoing radiotherapy: A randomized controlled trial
European Journal of Oncology Nursing 2024cited by 7position: middledoi
Effect of multicomponent exercise intervention in community dwelling frail elderly: A systematic review and meta-analysis
Archives of Gerontology and Geriatrics 2024cited by 5position: lastdoi
Exploring the immune landscape and drug prediction of an <scp>M2</scp> tumor‐associated macrophage‐related gene signature in <scp>EGFR</scp>‐negative lung adenocarcinoma
Thoracic Cancer 2024cited by 4position: middledoi
Comprehensive expression, prognostic and validation analysis of necroptosis-related lncRNAs in esophageal cancer
Translational Oncology 2024cited by 2position: middledoi
Corrigendum to “Comprehensive expression, prognostic and validation analysis of necroptosis-related lncRNAs in esophageal cancer” [Transl Oncol. 2024 Aug;46:101983.]
Translational Oncology 2024cited by 0position: middledoi
Prognostic gene HLA‐DMA associated with cell cycle and immune infiltrates in LUAD
The Clinical Respiratory Journal 2023cited by 6position: middledoi
The clinicopathological characteristics, gene mutation characteristics and survival analysis of carcinoma of unknown primary origin.
Journal of Clinical Oncology 2021cited by 0position: middledoi
Studies on the efficacy of pyrotinib in the treatment of HER-2 positive advanced solid tumors.
Journal of Clinical Oncology 2020cited by 2position: lastdoi
Efficacy and safety of fruquintinib in the treatment of poor patients with metastatic gastrointestinal cancer.
Journal of Clinical Oncology 2020cited by 0position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Xiaoyang Duan · Hebei Medical University5 papers (2023–2025)Yajie Huang · Hebei Medical University5 papers (2023–2025)Huazhen Du · Hebei Medical University3 papers (2024–2025)Chunyan Wang · Chinese PLA General Hospital3 papers (2024–2025)Jian Shi · Hebei Medical University3 papers (2024–2025)Da Jiang · Fourth Hospital of Hebei Medical University3 papers (2020–2021)Yanzhi Cui · Shanxi Medical University3 papers (2020–2021)Shaoshuang Fan · Hebei Medical University2 papers (2020–2020)Fang Huang · First People's Hospital of Yuhang District2 papers (2020–2020)Xinliang Zhou · Nanyang Technological University2 papers (2020–2021)Xue Zhang · Hebei Medical University2 papers (2020–2020)Long Wang · Tongji University2 papers (2020–2020)Lie Liu · Guangzhou University of Chinese Medicine2 papers (2024–2024)Wenya Song · Hebei Medical University1 papers (2021–2021) · 1 papers (2024–2024) · 1 papers (2024–2024)Zexian Hu · Hebei Medical University1 papers (2021–2021)Hongyu Shi · Harbin Medical University1 papers (2024–2024)Huijuan Wu · Fudan University1 papers (2024–2024)Yan Kong · Qingdao University1 papers (2020–2020)